首页>投融资

ADCendo

B轮

ADCendo is a biotech company focused on the development of novel targeted therapies for a selected number of bone, connective tissue and brain cancers, for which no targeted therapies currently exist.In April 2023, the company completed Series A extension financing, raising gross proceeds of 31 million EUR.In April 2023, BioInnovation Institute reported that following portfolio of Adcendo's Series A extension announcement issued over DKK 3 billion raised by BII's portfolio companies to date.In August 2019, the company had secured a convertible loan of DKK 10 million (US 1.49 million) for furthering its novel antibody-drug conjugates being developed for treatment of cancers. As part of the BioInnovation Institute (BII) Creation House program

https://adcendo.com/

470177

基本信息

公司全称

ADCendo ApS
类型

新型抗癌药物开发商
产业领域

药品研发/制造、医药研发/制造、生物药
公司人数

15人以下
地址

DK;
联系电话
邮箱

info@adcendo.dk
成立时间

2017-01-01

投融资

2024-11-25

B轮

1.35亿美元

Dawn Biopharma

Pontifax

诺和诺德

RA Capital

Logos Capital

Surveyor Capital

Venrock Capital

奥博资本

TPG Life Sciences Innovations
2023-04-04

A轮

3100万欧元

Ysios Capital Partners

诺和诺德

Pontifax

Gilde Healthcare

HealthCap

RA Capital
2021-04-29

A轮

5100万欧元

HealthCap

Ysios Capital Partners

RA Capital Management

Gilde Healthcare

Novo Seeds
2021-04-29

A轮

5100万欧元

诺和诺德

Ysios Capital Partners

RA Capital

Gilde Healthcare

HealthCap
加载更多

ADCendo

基本信息

投融资

相关投融资企业